Curaleaf Holdings, Inc. CURA CURLF has named Boris Jordan as
the new CEO, effective Friday, Aug. 16, 2024.
From his Wall Street roots in the 1980s to shaping one of the East Coast’s prominent cannabis firms, Jordan
has traversed a remarkable path.
Jordan’s career took flight on Wall Street in 1987 at the now-defunct Kidder Peabody, where he focused on
Latin America. Post the Soviet Union’s collapse in 1991, he assisted in Russian market reforms.
Embarking on a new chapter, cannabis magnet Boris Jordan joins Curaleaf Holdings, Inc.: Prospect and
Vision
By around 2013, Jordan had set his sights on the U.S. cannabis landscape. Drawing from his European
experiences, he likened navigating the U.S. cannabis sector to the challenges he faced in Russia – both
entailing formidable barriers.
Having been an initial investor in Curaleaf since 2014, he assumed the role of executive chairman in 2015,
a position he has aptly steered since.
“Since 2014, it has been a highlight of my career to focus on growing Curaleaf to become the leader of the
global cannabis industry as prohibition in the US and around the globe fades,” Jordan said in a press
release. “As I step into the CEO role to oversee all day-to-day operations, and navigate the strategic
direction of the company, I will work tirelessly for our customers, our shareholders, and our team members to ensure the company reaches its fullest
potential.”
Matt Darin, the current CEO, is set to retire. Darin expressed his intent to remain as a
special advisor until the year-end, ensuring a seamless handover.
“Over a decade ago, I set foot in the cannabis realm, contributing to the growth of the Grassroots brand,
eventually culminating in its acquisition by Curaleaf in 2020,” Darin expressed. “Taking part in this formative transaction which aided in birthing the world’s largest cannabis entity, and then steering the ship
as CEO, has been the pinnacle of my professional journey.”
The announcement was aligned with the company’s quarterly earnings call, where Curaleaf disclosed a
year-over-year revenue rise of 2% to $342 million for the second quarter, coupled with an adjusted EBITDA
of $73 million, representing 21.3% of revenue, and operating and free cash flow from ongoing operations
of $30 million and $6 million, respectively.
Delve into the latest insights: Unraveling CURLF’s Market Behavior
Curaleaf’s stock climbed 0.63% to $3.21 per share by the time of this writing on Thursday.
Photo: Boris Jordan interviewed at Benzinga Cannabis Capital Conference